CERC - European Cardiovascular Research Center
Founded by a group of physicians, CERC has a wide experience in clinical research. Their renown and expertise in this field have enabled them to generate optimal interaction with their industrial partners and other medical research teams focusing on the development of innovative techniques, concepts and treatments.
They provide unparalleled guidance and expert support in a broad range of clinical trials dedicated to the assessment of interventional coronary and peripheral revascularisation, structural and valvular heart disease treatments and adjunctive pharmacology.
Its objectives are to underpin European clinical trials and academic leadership, act as a global CRO and support young scientific leaders.
The CERC’s industrial partners attach great importance to finding cost-effective models which do not compromise quality.
Learn more: www.cerc-europe.org
A LEADING POSITION AND
AN INTERNATIONAL DEPLOYMENT
64 +
countries
involved
20 000 +
investigational
Centres
3 million +
patients
in database
50 000 +
users
worlwide
LATEST NEWSOUR NEWS >
June 26, 2025
June 30 – 4:00 PM to 5:15 PM (CET) xShare, an EU-funded project, strengthens procurement capabilities in digital health by translating the European Electronic Health Record Exchange Format (EEHRxF) into concrete requirements for tenders. This inaugural webinar presents key EU rules and promotes the procurement of interoperable solutions. It aims to raise awareness, share innovative […]
June 26, 2025
June 25–27 – JETRO – Japan External Trade Organization Pavilion – Osaka Booth Hall 6‑A, A‑0408 Philippe Haran – MD, is representing Telemedicine Technologies at the Japan Health Exhibition 2025, as a guest of Micron, Inc., a valued member of our CROAlliance partner. At Micron’s booth, he’s engaging with healthcare leaders and exploring collaboration opportunities […]
June 26, 2025
Applied Clinical Trials Online At a time when artificial intelligence (AI) is redefining industries at an unprecedented pace, the pharmaceutical sector stands on the brink of a progressive transformation. AI is not just a tool but a catalyst that promises to accelerate drug development timelines in ways we’ve never seen before. However, the true potential […]